Nephron recalls albuterol inhalation solution

Nephron Pharmaceuticals has announced a voluntary recall of ten lots of albuterol inhalation solution “as a precautionary measure, due to results from . . . internal monitoring processes.” The company says that it has not received reports of reportable adverse events for the 0.083% solution and that the lots met Nephron’s quality specifications when manufactured.

The lots involved in the recall are A3A33A, A3A33B, A3A34A, A3A35A, A3A36A, A3A37A, A3A38A, A3A40A, A3A41A, and A3A42A. Nephron has requested that retailers pull the lots from their shelves and is advising consumers to dispose of any inhalation solution from those lots.

The company added that it is “ready to work with every affected customer to ensure that the recall is not disruptive for the supply of this important drug product.”

Read the Nephron Pharmaceuticals press release.

Share

published on

May 10-May 14RDD 2026, Phoenix, AZ, USA

May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA

May 17-May 20: ATS International Conference 2026, Orlando, FL, USA

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan